Bicycle Therapeutics to Present Immune Oncology CD137 Data on Multivalent and Tumour-targeted Bispecific Bicycles at Peptides Congress

, a biotechnology company pioneering a new class of
therapeutics based on its proprietary bicyclic peptide (Bicycle®)
product platform, announced today that Punit Upadhyaya, Ph.D., Senior
Scientist at Bicycle, will present at the 6th Annual Peptides
Congress in London. The presentation, entitled “Bicycles as
T-cell Modulators: Activation of CD137 Using Multivalent and
Tumour-targeted Bicycle Peptides,” will take place on Thursday,
April 25, at 12:00 BST.

“Our T-cell targeting Bicycles are set apart from other
biological approaches because they are fully synthetic and modular,
which is designed to enable the rapid creation of molecules with unique
drug-like properties,” said Nicholas Keen, Ph.D., Chief Scientific
Officer of Bicycle Therapeutics. “We’re looking forward to sharing
research showcasing that our multivalent and tumour-targeted bispecific Bicycles
robustly activate CD137 positive T-cells in in vivo disease
models as well as in patient-derived material.”

About Bicycle Therapeutics

Bicycle Therapeutics is a clinical-stage biopharmaceutical company
developing a novel class of medicines, referred to as Bicycles®,
for diseases that are underserved by existing therapeutics. Bicycles are
fully synthetic short peptides constrained to form two loops that
stabilize their structural geometry. This constraint is designed to
confer high affinity and selectivity, and the relatively large surface
area presented by the molecule allows targets to be drugged that have
historically been intractable to non-biological approaches. We have a
novel and proprietary phage display screening platform that we use to
identify Bicycles in an efficient manner. Our initial internal
programs are focused on oncology indications with high unmet medical
need. Our lead product candidate, BT1718, is a Bicycle Toxin
Conjugate being investigated for safety, tolerability and efficacy in an
ongoing Phase I/IIa clinical trial in collaboration with, and fully
funded by, the Centre for Drug Development of Cancer Research UK.
Bicycle was founded in 2009 as a result of innovative science conducted
by Sir Greg Winter and Professor Christian Heinis. Sir Greg Winter is a
pioneer in monoclonal antibodies; in 2018, he was awarded a Nobel Prize
in chemistry for the invention of the technology underpinning our
proprietary phage display screening platform that we use to identify Bicycles.
Bicycle is headquartered in Cambridge, U.K., with many key functions and
members of its leadership team located near the biotech hub of Boston,
Massachusetts. For more information, visit BicycleTherapeutics.com,
connect with us on LinkedIn and follow us on Twitter at @Bicycle_tx.


Ten Bridge Communications
Sara Green
[email protected]

Argot Partners
Maeve Conneighton
[email protected]

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.